265 related articles for article (PubMed ID: 25094067)
1. Effects of a human VEGF antibody (Bevacizumab) on deprivation myopia and choroidal thickness in the chicken.
Mathis U; Ziemssen F; Schaeffel F
Exp Eye Res; 2014 Oct; 127():161-9. PubMed ID: 25094067
[TBL] [Abstract][Full Text] [Related]
2. Association between choroidal morphology and anti-vascular endothelial growth factor treatment outcome in myopic choroidal neovascularization.
Ahn SJ; Woo SJ; Kim KE; Park KH
Invest Ophthalmol Vis Sci; 2013 Mar; 54(3):2115-22. PubMed ID: 23462751
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of changes in choroidal neovascularization secondary to age-related macular degeneration after anti-VEGF therapy using spectral domain optical coherence tomography.
You JY; Chung H; Kim HC
Curr Eye Res; 2012 May; 37(5):438-45. PubMed ID: 22510011
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors of eyes with naïve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab.
Yang HS; Kim JG; Kim JT; Joe SG
Am J Ophthalmol; 2013 Dec; 156(6):1201-1210.e2. PubMed ID: 24075429
[TBL] [Abstract][Full Text] [Related]
5. Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia.
Chan WM; Lai TY; Chan KP; Li H; Liu DT; Lam DS; Pang CP
Retina; 2008 Oct; 28(9):1308-13. PubMed ID: 18728623
[TBL] [Abstract][Full Text] [Related]
6. Clinical and histological findings after intravitreal injection of bevacizumab (Avastin) in a porcine model of choroidal neovascularization.
Lassota N; Prause JU; Scherfig E; Kiilgaard JF; la Cour M
Acta Ophthalmol; 2010 May; 88(3):300-8. PubMed ID: 19416113
[TBL] [Abstract][Full Text] [Related]
7. Expression of vascular endothelial growth factor and intravitreal anti-VEGF therapy with bevacizumab in vasoproliferative retinal tumors.
Saito W; Kase S; Fujiya A; Dong Z; Noda K; Ishida S
Retina; 2013 Oct; 33(9):1959-67. PubMed ID: 23652580
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia.
Yamamoto I; Rogers AH; Reichel E; Yates PA; Duker JS
Br J Ophthalmol; 2007 Feb; 91(2):157-60. PubMed ID: 16870653
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal bevacizumab for extrafoveal choroidal neovascularization secondary to pathologic myopia.
Parodi MB; Iacono P; Papayannis A; Kontadakis S; Cascavilla ML; Zucchiatti I; Bandello F
Retina; 2013 Mar; 33(3):593-7. PubMed ID: 23190919
[TBL] [Abstract][Full Text] [Related]
10. Correlation of macular choroidal thickness with concentrations of aqueous vascular endothelial growth factor in high myopia.
Chen W; Song H; Xie S; Han Q; Tang X; Chu Y
Curr Eye Res; 2015 Mar; 40(3):307-13. PubMed ID: 25300046
[TBL] [Abstract][Full Text] [Related]
11. Photodynamic therapy combined with intravitreal injection of vascular endothelial growth factor antibody for polypoidal choroidal vasculopathy.
Moon SW; Kim MS; Kim ES; Yu SY; Kwak HW
Ophthalmologica; 2011; 225(3):169-75. PubMed ID: 21273795
[TBL] [Abstract][Full Text] [Related]
12. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab.
Peters S; Heiduschka P; Julien S; Ziemssen F; Fietz H; Bartz-Schmidt KU; ; Schraermeyer U
Am J Ophthalmol; 2007 Jun; 143(6):995-1002. PubMed ID: 17449002
[TBL] [Abstract][Full Text] [Related]
13. Transforming growth factor-beta in the chicken fundal layers: an immunohistochemical study.
Mathis U; Schaeffel F
Exp Eye Res; 2010 Jun; 90(6):780-90. PubMed ID: 20350541
[TBL] [Abstract][Full Text] [Related]
14. Prognosti implications of pigment epithelial detachment in bevacizumab (avastin)-treated eyes with age-related macular degeneration and choroidal neovascularization.
Freeman WR; Kozak I; Yuson RM; Nigam N; Cheng L; Mojana F
Retina; 2011 Oct; 31(9):1812-8. PubMed ID: 21866073
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
Retina; 2007; 27(4):432-8. PubMed ID: 17420694
[TBL] [Abstract][Full Text] [Related]
16. One-year outcomes of intravitreal bevacizumab (avastin) therapy for polypoidal choroidal vasculopathy.
Cheng CK; Peng CH; Chang CK; Hu CC; Chen LJ
Retina; 2011 May; 31(5):846-56. PubMed ID: 21317837
[TBL] [Abstract][Full Text] [Related]
17. Choroidal naevi complicated by choroidal neovascular membrane and outer retinal tubulation.
Papastefanou VP; Nogueira V; Hay G; Andrews RM; Harris M; Cohen VM; Sagoo MS
Br J Ophthalmol; 2013 Aug; 97(8):1014-9. PubMed ID: 23686326
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results.
Gharbiya M; Allievi F; Mazzeo L; Gabrieli CB
Am J Ophthalmol; 2009 Jan; 147(1):84-93.e1. PubMed ID: 18774547
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors for visual outcome after intravitreal anti-VEGF injection for naive myopic choroidal neovascularization.
Yoon JU; Kim YM; Lee SJ; Byun YJ; Koh HJ
Retina; 2012 May; 32(5):949-55. PubMed ID: 22534553
[TBL] [Abstract][Full Text] [Related]
20. Implications of bevacizumab on vascular endothelial growth factor and endostatin in human choroidal neovascularisation.
Tatar O; Shinoda K; Kaiserling E; Claes C; Eckardt C; Eckert T; Pertile G; Boeyden V; Scharioth GB; Yoeruek E; Szurman P; Bartz-Schmidt KU; ; Grisanti S
Br J Ophthalmol; 2009 Feb; 93(2):159-65. PubMed ID: 18838410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
